Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1936 to 1950 of 9044 results

  1. Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Nifedipine - Lidocaine for Chronic Anal Fissure [TSID 12093]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. iQoro neuromuscular training device, (MT809)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. MT656 Paige Prostate AI system for the detection of prostate cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  6. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Olezarsen for treating severe hypertriglyceridaemia [GID-TA12016]

    Awaiting development Reference number: GID-TA12016 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [GID-TA12005]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [GID-TA12010]

    Awaiting development Reference number: GID-TA12010 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Povorcitinib for treating non-segmental vitiligo [GID-TA12019]

    Awaiting development Reference number: GID-TA12019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Povorcitinib for treating prurigo nodularis [GID-TA12018]

    Awaiting development Reference number: GID-TA12018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development